Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go

被引:37
作者
Savic, L. J. [1 ]
Chapiro, J. [1 ]
Hamm, B. [1 ]
Gebauer, B. [1 ]
Collettini, F. [1 ]
机构
[1] Charite, Radiol, Augustenburger Pl 1, D-13353 Berlin, Germany
来源
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN | 2016年 / 188卷 / 08期
关键词
irreversible electroporation; pancreas; lung; prostate; liver; kidney; safety; interventional procedures; treatment effects; abdomen; thorax; ablation procedures; ablation; ADVANCED PANCREATIC ADENOCARCINOMA; TISSUE ABLATION; PROSTATE-CANCER; FOCAL THERAPY; SAFETY; TUMORS; LIVER; FEASIBILITY; EXPERIENCE; MANAGEMENT;
D O I
10.1055/s-0042-104203
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Irreversible electroporation (IRE) is the latest in the series of image-guided locoregional tumor ablation therapies. IRE is performed in a nearly nonthermal fashion that circumvents the, heat sink effect" and allows for IRE application in proximity to critical structures such as bile ducts or neurovascular bundles, where other techniques are unsuitable. IRE appears generally feasible and initial reported results for tumor ablation in the liver, pancreas and prostate are promising. Additionally, IRE demonstrates a favorable safety profile. However, site-specific complications include bile leaking or vein thrombosis and may be more severe after pancreatic IRE compared to liver or prostate ablation. There is limited clinical evidence in support of the use of IRE in the kidney. In contrast, pulmonary IRE has so far failed to demonstrate efficacy due to practicability limitations. Hence, this review will provide a state-of-the-art update on available clinical evidence of IRE regarding feasibility, safety and oncologic efficacy. The future role of IRE in the minimally invasive treatment of solid tumors will be discussed.
引用
收藏
页码:735 / 745
页数:11
相关论文
共 50 条
  • [41] Where We Were, Where We Are, Where We Are Going
    Epstein, Burton S.
    ANESTHESIA AND ANALGESIA, 2011, 113 (03) : 480 - 483
  • [42] Double Balloon Enteroscopy in Crohn's Disease: Where are We Now and Where Should We Go?
    Murphy, Seamus J.
    Kornbluth, Asher
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) : 485 - 490
  • [43] Leadless pacemakers: Where are we?
    Beccarino, Nicholas
    Saleh, Moussa
    Epstein, Laurence M.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2024, 34 (08) : 531 - 538
  • [44] Lymphedema of the Head and Neck-Where Do We Stand and Where We Are Headed
    Taylor, Ruby R.
    Pandey, Sonia K.
    Smartz, Taylor
    Chen, Wei F.
    Thaller, Seth R.
    JOURNAL OF CRANIOFACIAL SURGERY, 2024, 35 (07) : 2045 - 2048
  • [45] Environmental Behavior Framework Revisited: Where Do We Stand Ten Years Later and Where Do We Go from Here?
    Pelcher, Jamee A.
    Trendafilova, Sylvia
    McCullough, Brian P.
    SUSTAINABILITY, 2024, 16 (17)
  • [46] State of the art of research on Rivaroxaban: where we are and where we are going
    Vizzari, G.
    Ando, G.
    Piccione, M. Cusma
    Trio, O.
    Carerj, M. L.
    Luzza, F.
    Oreto, G.
    Zito, C.
    MULTIDISCIPLINARY APPROACH TO CARDIOVASCULAR DISEASES, 2016, : 97 - 102
  • [47] Living donor liver transplantation: where do we stand and where are we going?
    Lu, Hao
    Lu, Ling
    Zhang, Feng
    Zhai, Yuan
    Wang, Xuehao
    HEPATOBILIARY SURGERY AND NUTRITION, 2016, 5 (02) : 141 - 144
  • [48] Lead malfunctions in implantable cardioverter defibrillators: where are we and where should we go?
    Corrado, Andrea
    Gasparini, Gianni
    Raviele, Antonio
    EUROPACE, 2009, 11 (03): : 276 - 277
  • [49] Solid organ transplantation—where we are and how far can we possibly go?
    Jiri Fronek
    European Surgery, 2016, 48 : 130 - 134
  • [50] Networks in Public Administration Scholarship: Understanding Where We Are and Where We Need to Go
    Isett, Kimberley R.
    Mergel, Ines A.
    LeRoux, Kelly
    Mischen, Pamela A.
    Rethemeyer, R. Karl
    JOURNAL OF PUBLIC ADMINISTRATION RESEARCH AND THEORY, 2011, 21 : I157 - I173